Mary M Sugrue, MD, PhD

Locations

Annenberg Building Room 14-26A, 1468 Madison Ave, New York, NY, 10029

212-241-8352

Publications

Selected Publications

• The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q). Mikkael A. Sekeres, Arlene S. Swern, Aristoteles Giagounidis, Alan F. List, Dominik Selleslag, Moshe Mittelman, Brigitte Schlegelberger, Gudrun Göhring, Jack Shiansong Li, Mary M. Sugrue, Pierre Fenaux. Blood Cancer Journal
• Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. Xiaomei Ma, David P. Steensma, Bart L. Scott, Pavel Kiselev, Mary M. Sugrue, Arlene S. Swern. BMJ Open
• Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies. Rami Komrokji, Arlene S. Swern, David Grinblatt, Roger M. Lyons, Magnus Tobiasson, Lewis R. Silverman, Hamid Sayar, Ravi Vij, Albert Fliss, Nora Tu, Mary M. Sugrue. Oncologist